权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma

用于黑色素瘤 T 细胞治疗的 STING 激活聚合物纳米疫苗

基本信息

批准号：
10229423
负责人：
Jinming Gao
金额：
$ 53.55万
依托单位：
UT SOUTHWESTERN MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-30 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10229423
关键词：
Animals Antigens Cancer Center Cell physiology Clinical Clinical Data Combined Modality Therapy Cytotoxic T-Lymphocytes Dendritic Cells Dose Goals Guidelines Histology Human Papillomavirus Immune Immune checkpoint inhibitor Immune system Immunocompetent Individual Interferon Activation Interferon Type I Large Intestine Carcinoma Life MC38 Malignant Neoplasms Modeling Mus Mutate Nanotechnology Nature Organ Pathway interactions Patients Peptides Pharmacology Study Phase Polymers Production Proteins Protocols documentation Research Personnel Safety T cell response T cell therapy T-Lymphocyte Testing Therapeutic Tissues Toxic effect Tumor Antigens Tumor Immunity Vaccine Adjuvant Vaccines anti-CTLA4 anti-PD-1 arm cancer care cancer immunotherapy cancer therapy checkpoint inhibition checkpoint therapy chemotherapy clinical translation cytokine immunogenic immunotoxicity inhibitor/antagonist ipilimumab lymph nodes melanoma member nanoparticle nanovaccine neoantigens neoplasm immunotherapy novel pembrolizumab pre-clinical preclinical evaluation programs refractory cancer response spatiotemporal success synergism systemic toxicity tumor tumor microenvironment

项目摘要

Abstract Cancer immunotherapy is emerging as a new paradigm for the treatment of cancer by targeting the body's immune system instead of tumor. Clinical approvals of several check point inhibitors (e.g., Ipilimumab, Pembrolizumab) have shown durable response in a small subset of melanoma patients over conventional chemotherapy. Despite these successes, many cancers are poorly immunogenic and do not generate adequate cytotoxic T lymphocytes (CTLs) and therefore these patients cannot benefit from immune checkpoint therapies. The long-term goal of this application is to establish STING-activating polymeric nanovaccines for cytotoxic T cell therapy of melanoma. We will capitalize on the discovery of an ultra-pH sensitive polymer (PC7A) that allows optimal spatio-temporal orchestration of cytosolic delivery of tumor antigen (Ag) in dendritic cells and innate stimulation for the robust production of tumor-specific CTLs. A simple physical mixture of Ag-PC7A NP resulted in a robust Th1 and CTL (>80%) response without the need of innate stimulants (i.e., CpG, Poly(I:C)). Use of tumor associated antigens (TAAs) have shown significantly increased antitumor efficacy in a B16F10 melanoma model in mice. We will test the central hypothesis that PC7A nanoparticle vaccine will synergize with checkpoint inhibition to allow a safe and efficacious T cell therapy of melanoma. There are three specific aims: (1) Expand the nanovaccine platform to multiple melanoma peptide antigens; (2) Evaluate the safety of the polymeric nanovaccines in healthy, immunocompetent animals; and (3) Evaluate the antitumor efficacy of the polymer nanovaccines and its synergy with checkpoint inhibition. Accomplishments of the above aims will provide critical data for clinical translation of the nanovaccines for melanoma therapy. We will also collaborate with other nanoalliance members to test the PC7A NP in additional cancer indications.

摘要癌症免疫疗法正在成为靶向治疗癌症的新范式身体的免疫系统而不是肿瘤。几种检查点抑制剂的临床批准(例如， Ipilimumab，pembrolizumab)在一小部分黑色素瘤患者中显示出持久的疗效而不是常规化疗。尽管取得了这些成功，但许多癌症的免疫原性很差。并且不能产生足够的细胞毒性T淋巴细胞(CTL)，因此这些患者不能从免疫检查点疗法中受益。此应用程序的长期目标是建立用于黑色素瘤细胞毒性T细胞治疗的刺激性聚合物纳米疫苗。我们将利用这一点关于一种超pH敏感聚合物(PC7A)的发现树突状细胞胞浆递送肿瘤抗原及天然刺激作用的研究强劲的肿瘤特异性CTL的产生。Ag-PC7A NP的简单物理混合物导致了强大的Th1和CTL(&gt；80%)反应，不需要天生的刺激物(即CpG，Poly(I：C))。使用肿瘤相关抗原(TAA)的研究表明，在一种小鼠B16F10黑色素瘤模型的建立。我们将检验PC7A纳米颗粒疫苗的中心假设将与检查点抑制协同作用，以实现安全有效的黑色素瘤T细胞治疗。具体有三个目标：(1)将纳米疫苗平台扩展到多种黑色素瘤多肽 (2)评价聚合纳米疫苗在健康、有免疫能力的人群中的安全性动物；和(3)评价聚合物纳米疫苗的抗肿瘤效果及其与检查点抑制。上述目标的实现将为临床提供关键数据用于黑色素瘤治疗的纳米疫苗的翻译。我们还将与其他纳米联盟成员测试PC7A NP在其他癌症适应症中的作用。